• Je něco špatně v tomto záznamu ?

Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin

M. Studenovsky, K. Ulbrich, M. Ibrahimova, B. Rihova

. 2011 ; 42 (1-2) : 156-163.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027286

This paper describes the synthesis and biological evaluation of a conjugate of the highly cytotoxic drug 2-pyrrolinodoxorubicin (p-DOX) with an N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) as a water-soluble biocompatible polymer carrier, utilizing the advantageous concept of polymer-drug conjugates. The conjugate of p-DOX with HPMA copolymer (PHPMA/p-DOX) was prepared by reacting the PHPMA/DOX conjugate, where the DOX was bound via a hydrazone bond, with 4-iodobutyraldehyde. The hydrazone bond between the polymer and drug is susceptible to pH-controlled hydrolysis, enabling prolonged stability in circulation and fast p-DOX release under conditions mimicking the intracellular environment. The in vitro cytostatic activity of free p-DOX was in accordance with literature, whereas its PHPMA conjugate exhibited a 1.3- to 5-fold lower cytotoxicity, depending on the cancer cell line, when compared to the free p-DOX. This is in qualitative agreement with the data obtained for DOX and its HPMA copolymer conjugates. On mice bearing T-cell EL4 lymphoma, no tumor suppression was observed from the free p-DOX at a subtoxic dose of 0.1 mg/kg, whereas the PHPMA/p-DOX conjugate significantly inhibited the initial tumor growth at approximately equitoxic doses of 0.4 and 0.8 mg p-DOX eq/kg. However, moderately elevated doses of the p-DOX equivalent in the conjugate caused toxic effects, making accurate dosage setting essential.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027286
003      
CZ-PrNML
005      
20160316125243.0
007      
ta
008      
120816s2011 ne f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.ejps.2010.11.006 $2 doi
035    __
$a (PubMed)21075206
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Studenovský, Martin $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Sq. 2, Prague 6, Czech Republic. studenovsky@imc.cas.cz $7 xx0110491
245    10
$a Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin / $c M. Studenovsky, K. Ulbrich, M. Ibrahimova, B. Rihova
520    9_
$a This paper describes the synthesis and biological evaluation of a conjugate of the highly cytotoxic drug 2-pyrrolinodoxorubicin (p-DOX) with an N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) as a water-soluble biocompatible polymer carrier, utilizing the advantageous concept of polymer-drug conjugates. The conjugate of p-DOX with HPMA copolymer (PHPMA/p-DOX) was prepared by reacting the PHPMA/DOX conjugate, where the DOX was bound via a hydrazone bond, with 4-iodobutyraldehyde. The hydrazone bond between the polymer and drug is susceptible to pH-controlled hydrolysis, enabling prolonged stability in circulation and fast p-DOX release under conditions mimicking the intracellular environment. The in vitro cytostatic activity of free p-DOX was in accordance with literature, whereas its PHPMA conjugate exhibited a 1.3- to 5-fold lower cytotoxicity, depending on the cancer cell line, when compared to the free p-DOX. This is in qualitative agreement with the data obtained for DOX and its HPMA copolymer conjugates. On mice bearing T-cell EL4 lymphoma, no tumor suppression was observed from the free p-DOX at a subtoxic dose of 0.1 mg/kg, whereas the PHPMA/p-DOX conjugate significantly inhibited the initial tumor growth at approximately equitoxic doses of 0.4 and 0.8 mg p-DOX eq/kg. However, moderately elevated doses of the p-DOX equivalent in the conjugate caused toxic effects, making accurate dosage setting essential.
650    _2
$a zvířata $7 D000818
650    _2
$a antibiotika antitumorózní $x aplikace a dávkování $x škodlivé účinky $x chemická syntéza $x chemie $x terapeutické užití $7 D000903
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a doxorubicin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x chemická syntéza $x chemie $x terapeutické užití $7 D004317
650    _2
$a nosiče léků $x chemická syntéza $x chemie $7 D004337
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lymfom T-buněčný $x farmakoterapie $x patologie $7 D016399
650    _2
$a myši $7 D051379
650    _2
$a molekulární struktura $7 D015394
650    _2
$a kyseliny polymethakrylové $x chemická syntéza $x chemie $7 D011109
650    _2
$a pyrroly $x aplikace a dávkování $x škodlivé účinky $x chemická syntéza $x chemie $x terapeutické užití $7 D011758
650    _2
$a rozpustnost $7 D012995
650    _2
$a xenogenní modely - testy antitumorózní aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ulbrich, Karel, $d 1947- $7 jo2004259877 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic
700    1_
$a Jelínková-Ibrahimová, Markéta $7 xx0096917 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Prague 4, Czech Republic
700    1_
$a Říhová, Blanka, $d 1942- $7 jo20000073671 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Prague 4, Czech Republic
773    0_
$w MED00001639 $t European journal of pharmaceutical sciences official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 42, č. 1-2 (2011), s. 156-163
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21075206 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160316125002 $b ABA008
999    __
$a ok $b bmc $g 949328 $s 784632
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 42 $c 1-2 $d 156-163 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
LZP    __
$b NLK112 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...